Abbott Laboratories logo
Abbott Laboratories (ABT)
Compare

ABT Income Statement

Revenue, expenses, and profitability analysis

ABT Quarterly Income Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
25.446B6.283B6.537B6.338B6.288B5.444B5.598B5.426B5.305B
45.134B11.164B11.459B11.369B11.142B10.358B10.974B10.635B10.377B
Cost of Goods Sold
19.688B4.881B4.922B5.031B4.854B4.914B5.376B5.209B5.072B
56.3%56.3%57.0%55.7%56.4%52.6%51.0%51.0%51.1%
Total Operating Expenses
17.271B4.441B4.286B4.308B4.236B3.756B3.608B3.608B3.619B
3.008B756.000M735.000M785.000M732.000M703.000M728.000M713.000M697.000M
12.588B3.263B3.129B3.103B3.093B3.053B2.880B2.895B2.922B
8.202B1.842B2.251B2.057B2.052B1.688B1.990B1.818B1.686B
16.5%16.5%19.6%18.1%18.4%16.3%18.1%17.1%16.2%
8.137B1.449B2.358B2.180B2.150B1.778B2.030B1.940B1.607B
Interest Income
148.000M77.000M71.000M82.000M91.000M91.000M82.000M
275.000M68.000M42.000M44.000M121.000M134.000M152.000M166.000M168.000M
Other Income/Expense
-65.000M-393.000M107.000M123.000M98.000M90.000M40.000M122.000M-79.000M
6.276B1.077B1.776B1.644B1.779B1.325B9.229B1.646B1.302B
1.861B372.000M582.000M536.000M371.000M453.000M-7.199B294.000M305.000M
9.6%9.6%15.5%14.5%16.0%12.8%84.1%15.5%12.5%
10.804B1.842B2.822B3.092B3.048B2.668B2.989B2.907B2.580B
EBITDA Margin
16.5%16.5%24.6%27.2%27.4%25.8%27.2%27.3%24.9%
1.990B0.00422.000M791.000M777.000M756.000M807.000M801.000M805.000M
EPS Basic
3.600.621.020.941.020.765.330.950.75
3.590.621.020.941.010.765.270.940.74
Shares Outstanding
1.747B1.747B1.747B1.749B1.740B1.747B1.732B1.734B1.734B
Diluted Shares Outstanding
1.747B1.747B1.747B1.749B1.751B1.747B1.746B1.748B1.751B

ABT Annual Income Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
24.607B21.325B20.037B22.323B23.214B17.377B16.693B15.823B
44.328B41.950B40.109B43.653B43.075B34.608B31.904B30.578B
Cost of Goods Sold
19.721B20.625B20.072B21.330B19.861B17.231B15.211B14.755B
55.5%50.8%50.0%51.1%53.9%50.2%52.3%51.7%
Total Operating Expenses
16.586B14.474B13.602B13.961B14.014B12.086B12.102B11.979B
2.955B2.823B2.719B2.852B2.738B2.418B2.408B2.288B
12.378B11.651B10.883B11.109B11.276B9.668B9.694B9.691B
8.048B6.825B6.435B8.362B9.200B5.291B4.591B3.844B
18.2%16.3%16.0%19.2%21.4%15.3%14.4%12.6%
8.466B7.013B6.664B8.306B8.211B4.968B4.077B2.873B
Interest Income
230.000M344.000M385.000M183.000M43.000M46.000M94.000M105.000M
341.000M603.000M698.000M315.000M410.000M708.000M818.000M729.000M
Other Income/Expense
418.000M188.000M229.000M-56.000M-989.000M-323.000M-514.000M-971.000M
6.524B13.402B5.723B6.933B7.071B4.495B3.687B2.368B
1.942B-6.389B941.000M1.373B1.140B497.000M390.000M539.000M
14.7%31.9%14.3%15.9%16.4%13.0%11.6%7.7%
11.553B10.834B10.605B11.888B12.159B9.003B7.909B6.880B
EBITDA Margin
26.1%25.8%26.4%27.2%28.2%26.0%24.8%22.5%
2.746B3.218B3.243B3.267B3.538B3.327B3.014B3.278B
EPS Basic
3.747.673.303.943.972.522.071.35
3.727.643.273.913.942.502.061.34
Shares Outstanding
1.747B1.732B1.734B1.753B1.775B1.773B1.768B1.756B
Diluted Shares Outstanding
1.747B1.748B1.749B1.764B1.789B1.786B1.781B1.770B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Abbott Park, IL
114,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford